Sleep Disorder Devices Market Size, Share, Future Analysis, 2026-2034

Market Overview

According to fortune business insights, the global sleep disorder devices market size was valued at USD 23.28 billion in 2025. The market is projected to grow from USD 25.33 billion in 2026 to USD 44.40 billion by 2034, exhibiting a CAGR of 7.3% during the forecast period. North America dominated the sleep disorder devices market with a market share of 45.44% in 2025.

The analysis shows that major companies are investing more in sleep disorder devices as the prevalence of sleep diseases rises. For example, the increasing number of sleep studies and the development of healthcare systems are leading to a higher adoption rate. This trend indicates a strong demand for sleep disorder devices worldwide.

Major Players Profiled in the Market Report:

• Resmed (U.S.)

• Fisher & Paykel Healthcare Limited (New Zealand)

• Koninklijke Philips N.V. (Netherlands)

• Inspire Medical Systems, Inc. (U.S.)

• ZOLL Medical Corporation (U.S.)

• Compumedics Limited (Australia)

• Cadwell Industries Inc. (U.S.)

• React Health (U.S.)

• Löwenstein Medical SE & Co. KG (Germany)

• SomnoMed (Australia)

Segments

Increasing Cases of Sleep Disorders to Propel Therapeutics Segment GrowthBased on product type, the market is divided into diagnostic and therapeutic. The therapeutic segment holds the largest market share, driven by the increasing prevalence of sleep disorders, which results in a growing demand for therapeutic devices like CPAP machines.

High Prevalence of Sleep Disorders to Drive Adult Segment ExpansionBy age group, the market is categorized into adults and pediatrics. The adults segment is leading the market due to the high prevalence of sleep disorders such as sleep apnea and insomnia within this demographic, leading to greater demand for both diagnostic and therapeutic products.

Growing Occurrence of Chronic Conditions to Drive Sleep Apnea Segment DominanceBased on disorder type, the market is segmented into sleep apnea, insomnia, Restless Leg Syndrome (RLS), and others. The sleep apnea segment holds the largest market share owing to the growing global prevalence of the condition, which increases patient admissions and boosts demand for diagnostic and treatment devices.

Increasing Preference for Convenience to Make Homecare Settings the Leading End UserBased on end user, the market is segmented into sleep laboratories & clinics, homecare settings, and others. The homecare settings segment holds the largest market share owing to the high preference among consumers for the convenience and comfort of using sleep disorder devices at home.

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Report Coverage

The report offers:

• Major growth drivers, restraining factors, opportunities, and potential challenges for the market.

• Comprehensive insights into regional developments.

• List of major industry players.

• Key strategies adopted by the market players.

• The latest industry developments include product launches, partnerships, mergers, and acquisitions.

For detailed market insights: https://www.fortunebusinessinsights.com/sleep-disorder-devices-market-117906

Drivers & Restraints

Increasing Prevalence of Sleep Disorders to Propel Market GrowthThe rapid growth in the prevalence of chronic sleep disorders, including sleep apnea and insomnia, has raised the demand for diagnostic and treatment devices. As awareness about sleep health increases and healthcare infrastructure expands, more patients are seeking diagnosis and treatment, which is boosting the sleep disorder devices market growth.

However, the high cost associated with diagnosis and treatment may hamper market growth. Expenses for specialist consultations, sleep studies (polysomnography), and the long-term cost of devices like CPAP machines and accessories can be substantial, limiting access for some patients, particularly in markets with limited reimbursement.

Regional Insights

High Prevalence of Sleep Disorders in the U.S. Propels Market Growth in North AmericaNorth America holds the dominant sleep disorder devices market share and is projected to experience growth during the forecast period. The region’s growth is attributed to the high prevalence of sleep disorders, strong demand for diagnostic and therapeutic devices, and the presence of advanced healthcare infrastructure.

Asia Pacific is one of the fastest-growing regions in the market. The growth is attributed to the development of healthcare infrastructure, rising healthcare expenditure, and growing awareness of sleep health in developing nations, including China and India.

Sleep Disorder Devices Market Future Growth:

The sleep disorder devices market is experiencing robust growth, fueled by rising consumer interest in preventive health and the adoption of digital health technologies. Today's consumers are increasingly drawn to wearable devices like smartwatches, fitness bands, and smart rings that can monitor sleep stages, heart rate, and respiratory patterns. This trend enables users to identify potential sleep issues early and seek medical consultation. Additionally, the integration of sleep data into mobile health apps and the expansion of telehealth-based sleep management solutions are key growth drivers, making sleep monitoring more accessible and facilitating long-term patient engagement.

Competitive Landscape

Increasing Number of Product Launches to Propel Market GrowthThe market features prominent players like Resmed and Fisher & Paykel Healthcare Limited. These leading companies are accelerating growth through strategic initiatives such as maintaining a robust and diversified product portfolio, new product launches, and a strong focus on research and development. Their proactive approach to innovating and expanding their offerings continues to fuel the market’s momentum.

Key Industry Development

• May 2026: Resmed acquired Noctrix Health, manufacturer of the Nidra device, for a purchase price of USD 340 million to strengthen its product channel.

• September 2025: Compumedics Limited received U.S. FDA approval for its Somfit D device, authorizing its sale in the U.S.